Overexpression of CDCA8 predicts poor prognosis and drug insensitivity in lung adenocarcinoma

• Published in: BMC medical genomics Vol. 17; no. 1; pp. 265 - 18
• Main Authors: Gu, Huiquan, Gao, Xinzheng, Han, Wenlong, Wang, Fangyu, Zhang, Hanqiang, Yao, Longyu, Chen, Weimin, Liu, Qiang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.11.2024; BioMed Central; BMC
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - metabolism; Adenocarcinoma of Lung - pathology; Aged; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic drugs; Biomarker; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cancer; Cancer therapies; CDCA8; Cell cycle; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell division; Datasets; Diagnosis; Drug development; Drug resistance; Drug Resistance, Neoplasm - genetics; Drug therapy; Female; Gene expression; Gene Expression Regulation, Neoplastic; Gene silencing; Genes; Genetic aspects; Helper cells; Humans; Immunohistochemistry; Immunosuppressive agents; Infiltration; Leukocytes (eosinophilic); LUAD; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Lymphocytes T; Male; Mast cells; Medical prognosis; Metastases; Middle Aged; Nomograms; Oncology, Experimental; p53 Protein; Patients; Prognosis; Proteins; Regression analysis; RNA-mediated interference; Sensitivity; Sensitivity analysis; Stem cells; Survival analysis; Tumors; China; CDCA8; Biomarker; Sensitivity; Prognosis; LUAD
• DOI: 10.1186/s12920-024-02019-x
• ISSN: 1755-8794

Lung adenocarcinoma (LUAD) accounts for the highest proportion of lung cancers; however, specific biomarkers are lacking for diagnosis, treatment, and prognostic assessment. Cell division cycle-associated 8 (CDCA8) is a cell cycle regulator with elevated expression in various cancers. However, the association between CDCA8 expression and LUAD prognosis remains unclear. The association between CDCA8 and LUAD prognosis was evaluated based on the The Cancer Genome Atlas (TCGA) dataset, and CDCA8 related functions were determined using gene enrichment and gene ontology analyses. We also analyzed the association between CDCA8 expression and immune cell infiltration. Immunohistochemistry was used to determine the differential expression of CDCA8 in tumors and controls. Finally, we evaluated the differences in the sensitivity of different levels of CDCA8 to different anticancer drugs in LUAD. CDCA8 expression was significantly higher in primary LUAD tumors than in normal tissues (P < 0.001). Moreover, Kaplan-Meier survival analysis demonstrated that high CDCA8 expression predicted poor survival in patients with LUAD (P = 0.006). The receiver operating characteristic (ROC) curves indicated that CDCA8 was an effective guide for the diagnosis of LUAD. Functional annotation indicated that CDCA8 might be involved in functions such as p53 stabilization, nucleotide metabolism, RNA-mediated gene silencing, and the G2/M phase checkpoint. Immune infiltration results suggested that CDCA8 was positively correlated with Th2 cells and Tgd and negatively correlated with Eosinophils and Mast cells (P < 0.01). In addition, elevated expression of CDCA8 may increase the sensitivity of patients to certain anticancer drugs. CDCA8 upregulation is significantly associated with poor survival and immune infiltration in patients with LUAD. Our study suggests that CDCA8 can be used as a biomarker for LUAD prognosis and a reference for personalized medication.